Imaging benign inflammatory syndromes

AbstractBenign mastitis is a rare disease and its management is difficult. The diagnostic challenge is to distinguish it from carcinomatous mastitis. We make a distinction between acute mastitis secondary to an infection, to inflammation around a benign structure or to superficial thrombophlebitis, and chronic, principally plasma cell and idiopathic granulomatous mastitis. Imaging is often non-specific but we need to know and look for certain ultrasound, mammogram or magnetic resonance imaging (MRI) signs to give a pointer as early as possible towards a benign aetiology. A biopsy should be undertaken systematically where there is the slightest diagnostic doubt, to avoid failing to recognise a carcinomatous mastitis

RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Advanced, unresectable hepatocellular carcinoma (HCC) has a poor prognosis with median life expectancy of approximately 1 year. Overexpression of PD-L1 in tumor cells and PD-1 on tumor-infiltrating T cells has been associated with poorer prognosis, more advanced disease and higher recurrence rates in HCC. Monoclonal antibodies against PD-1 have demonstrated antitumor activity in patients with solid tumors, including HCC. Tislelizumab, an investigational, humanized IgG4 monoclonal antibody with high affinity and binding specificity for PD-1, has demonstrated preliminary antitumor activity in HCC. Here we describe a head-to-head Phase III study comparing the efficacy, safety and tolerability of tislelizumab with sorafenib as first-line treatment in unresectable HCC

L'effet de la superoxyde dismutase sur le système nerveux central irradié à propos d'études pilotes expérimentales chez le rat

Il a été constaté que la superoxyde dismutase bovine (SOD) pouvait faire régresser certaines complications chroniques de la radiothérapie. Pour cette raison cette enzyme a été utilisée chez le rat pour traiter des encéphalites radiques étudiées par le test de l'évitement actif bilatéral. La SOD a permis une régression significative des troubles dans deux études d'encéphalite chronique et deux études d'encéphalite aiguë. Par ailleurs une autre étude a montré que la SOD prévenait les troubles cognitifs engendrés par un stimulus douloureux important. Ainsi la SOD s'est révélée capable d'améliorer les performances cérébrales après une agression spécifique (radiothérapie) ou non spécifique (stimulus douloureux important). Cette constatation ouvre des perspectives intéressantes pour la thérapeutique